Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Buoyant Biocon Bullish On US Biosimilar Interchangeability

Executive Summary

Ahead of an expected FDA review of its biosimilar trastuzumab later this year, the chair of major Indian biologics company Biocon is positive over the still evolving area of biosimilar interchangeability, saying new US draft guidance is “very welcome.”


Related Content

Biosimilars: Postmarketing Data Alone Not Enough For Interchangeability
Pfizer's Herceptin Biosimilar Moving Forward Amid Rising Competition
Biocon/Fujifilm Enter Lantus Biosimilar Fray In Japan


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts